The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma

Background. Prostate specific antigen (PSA) is useful as a tumor marker for monitoring patients with prostate cancer after definitive therapy. Limitations have been noted when PSA was used for the early detection of prostate cancer. The use of prostate specific antigen density [PSAD = PSA (ng/ml)/prostate volume (cc)] has been suggested to differentiate benign from malignant prostate disease.

[1]  W. Ellis,et al.  The inability of prostate specific antigen index to enhance the predictive the value of prostate specific antigen in the diagnosis of prostatic carcinoma. , 1993, The Journal of urology.

[2]  P. Pavlica,et al.  Correlation between prostate-specific antigen and prostate volume, evaluated by transrectal ultrasonography: usefulness in diagnosis of prostate cancer. , 1990, European urology.

[3]  A. Pantuck,et al.  Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. , 1992, The Journal of urology.

[4]  J. Oesterling,et al.  Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. , 1991, The Journal of urology.

[5]  T. Stamey,et al.  Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. , 1988, The New England journal of medicine.

[6]  Controversies in management of apparently localized carcinoma of prostate. , 1989, Urology.

[7]  R L Vessella,et al.  Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. , 1987, The Journal of urology.

[8]  P. Lange,et al.  Serum prostate-specific antigen: its use in diagnosis and management of prostate cancer. , 1989, Urology.

[9]  G. Murphy,et al.  Prostate antigen: A new potential marker for prostatic cancer , 1981, The Prostate.

[10]  T. Stamey,et al.  Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. , 1989, The Journal of urology.

[11]  R. Vessella,et al.  The enhanced detection of persistent disease after prostatectomy with a new prostate specific antigen immunoassay. , 1993, The Journal of urology.

[12]  M. Benson,et al.  The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. , 1992, The Journal of urology.